
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is developing silevertinib, a fourth-generation EGFR MasterKey inhibitor, currently undergoing Phase 2 clinical trials for treating EGFR mutant non-small cell lung cancer (NSCLC), which has demonstrated a compelling clinical overall response rate (cORR) of 60%. The company anticipates significant value inflection points from upcoming trial results, particularly for first-line treatment opportunities which are estimated to be in a lucrative market exceeding $1 billion, thus strengthening the perception of silevertinib's efficacy against competitors. Moreover, the favorable outlook for silevertinib is supported by its broad activity across various oncogenic mutations and its demonstrated brain penetration, addressing crucial aspects of treatment for patients with actionable mutations.
Bears say
The analysis of Black Diamond Therapeutics Inc. indicates significant concerns regarding the efficacy and competitive positioning of its lead therapy, silevertinib, in treating patients with EGFR mutant non-small cell lung cancer (NSCLC). The lower clinical overall response rate (cORR) observed in silevertinib compared to competing therapies raises doubts about the drug's ability to gain traction in the market, particularly as high rates of adverse effects have resulted in substantial treatment interruptions and dose reductions. Additionally, the company's current market capitalization of approximately $230 million reflects a lack of investor confidence in silevertinib’s potential for successful outcomes in clinical trials, exacerbating the negative outlook for the stock.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares